The daily fatalities remained below 1,000 for the second consecutive day, according to the Union health ministry.
India saw 37,566 new cases being reported in a day, while the Covid-19 death toll rose to 3,97,637 with 907 daily fatalities, the lowest in 77 days.
Asking the states to regularly monitor the districts with a high number of active coronavirus cases, the Union home ministry issued an advisory to all the state governments and Union territory administrations on Covid-19 management for the month of July.
Here’s the Covid-19 roundup-
MHA tells states to focus on five-fold strategy of Covid management
The Centre asked the states on Tuesday to focus on the five-fold strategy for effective Covid-19 management and said the process of relaxing restrictions should be carefully calibrated.
In an advisory to all the state governments and Union Territory administrations on Covid-19 management for the month of July, Union Home Secretary Ajay Bhalla also said the states should regularly monitor the districts with a high number of active coronavirus cases per million (10 lakh) population as it is an important indicator to predict the need for upgrading the health infrastructure and logistics, so that early and prompt action can be taken.
He said with the decline in the number of active coronavirus cases, many states have started relaxing the restrictions.
Moderna gets nod as 4th Covid vaccine in India, Pfizer next
The Centre on Tuesday granted approval to the Moderna Covid-19 vaccine to enter the Indian market as the fourth vaccine in its arsenal to fight the deadly pandemic, adding that the next in line is the Pfizer vaccine.
Member of NITI Aayog, V.K. Paul, made the announcement at a press conference, saying that “new drug permission has been granted to Moderna, the first internationally developed Covid vaccine”.
Paul, however, made it clear that the new drug permission is for restricted use and that Moderna will be administered in two doses.
Moderna thus became the fourth vaccine which has been approved by the Drugs Controller General of India (DCGI) after AstraZeneca’s Covishield, Bharat Biotech’s Covaxin and Sputnik V developed by Russia’s Gamaleya Institute.
Russia’s Sputnik V shot around 90% effective against Delta variant
Russia’s Sputnik V vaccine is around 90% effective against the Delta variant of coronavirus, the RIA news agency cited Denis Logunov, deputy director of the Gamaleya Institute that developed the vaccine, as saying on Tuesday.
The shot was previously found by the researchers to be almost 92% effective against the original strain of coronavirus.
Logunov said the Delta variant efficacy figure was calculated based on information from digital medical records and on vaccination records.
Five Indian drugmakers to jointly start trial of Merck & Co’s Covid-19 drug
Five Indian generic drugmakers, including Cipla and Dr Reddy’s Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co’s anti-viral drug to treat mild Covid-19 in non-hospitalised patients in India.
Between March and April, each of these companies, which also include Sun Pharmaceutical Industries, Torrent Pharmaceuticals and privately held Emcure Pharmaceuticals, partnered with Merck to expand production of the drug, molnupiravir.
The partnership gives the companies license to supply molnupiravir to India and more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies, Merck said in late April.
Concerned over Delta Plus variant of Covid-19, Punjab CM orders extension of curbs till July 10
With cases of Delta Plus variant of Covid-19 coming to light, Punjab Chief Minister Captain Amarinder Singh on Tuesday ordered extension of the coronavirus restrictions till July 10, with certain more relaxations, including the opening of bars, pubs with 50 per cent capacity, beginning July 1.
Skill development centres and universities have also been allowed to open with conditions that staff and students must have taken at least one dose of vaccine. IELTS coaching institutes were already allowed to be opened, subject to students and staff have taken at least one dose of vaccine, the press release said.
Co-Win platform can be customised, scaled up for health intervention across globe: India at UNSC
The CoWin app, a “scalable, inclusive and open technological” platform developed by India, can be customized and scaled up for health interventions across the globe, Foreign Secretary Harsh Vardhan Shringla said on Tuesday.
Speaking at UNSC open debate on “Maintenance of International Peace and Security: Cyber Security,” Shringla said India is working on sharing the platform with partner countries.
CoWIN (Covid Vaccine Intelligence Work) is an app introduced by the Government of India for the vaccination process. It is used for registration and appointment for vaccination against Covid-19.
“As part of its Covid vaccination drive, one of the largest such drives in the world, India has developed CoWIN – a scalable, inclusive and open technological platform,” Shringla said in his remarks through video conferencing.
US announces $41 million additional Covid19 assistance to India
The US has announced an additional USD 41 million assistance to help India respond to the Covid-19 pandemic and strengthen the country’s preparedness for the future health emergencies, taking the total aid to more than USD 200 million.
In April and May, India struggled with the second wave of the Covid-19 pandemic with more than 3,00,000 daily new cases. Hospitals were reeling under a shortage of medical oxygen and beds.
“India came to the assistance of the United States during this country’s time of need, and now the United States stands with the people of India as they continue to battle the Covid-19 pandemic,” the US Agency for International Development said on Monday.
Over 33 crore Covid vaccine doses administered in country: Govt
The cumulative number of Covid-19 vaccine doses administered in the country has crossed the landmark of 33 crore, the health ministry said on Tuesday.
A total of 33,25,81,423 vaccine doses have been administered in the country, including over 33.79 lakh (33,79,525) on Tuesday, according to a provisional report compiled at 7 pm.
The ministry said 19,42,308 beneficiaries in the 18-44 age group received the first dose while 78,039 were administered the second dose of the vaccine on Tuesday.
Cumulatively, 8,99,01,981 people in the 18-44 age group have received the first dose and 20,81,948 have been given the second dose of the vaccine since the start of the third phase of the nationwide vaccination drive.
Have some authority to certify if candidate can’t take CA exams due to Covid issues: SC to ICAI
The Supreme Court on Tuesday asked the Institute of Chartered Accountants of India (ICAI) to look into “all angles” and consider having a competent authority to certify that a candidate of CA examinations scheduled in July is unable to appear due to Covid-19 related issues.
Observing that having a negative RT-PCR report may not reflect the fitness of a person as the effects of coronavirus may be felt for months, the apex court said that ICAI should look into all the aspects as the matter relates to granting an opportunity to opt-out to those who can’t appear in exams due to Covid related issues.
The CA exams, conducted by the ICAI in May, were postponed due to the Covid-19 pandemic and are scheduled to be held from July 5-20.
Kerala extends lockdown with TPR based classification of local bodies
With Covid-19 cases not witnessing the expected decline, the Kerala government on Tuesday decided to extend lockdown restrictions for one more week.
The state reported 13,550 new cases on Tuesday, taking the cumulative cases to 29,10,507 while the toll mounted to 13,093 with the addition of 104 recent deaths.
Briefing the media after the Covid review meeting, Chief minister Pinarayi Vijayan said it hasbeen decided to make small changes in the classification of areas according to the spread of the disease.
The LSG bodies have been reclassified on the basis of the average (Test Positivity Rate (TPR) for the last seven days.
Bharat Biotech chairman given central security cover
Krishna Ella, the chairman of vaccine manufacturer Bharat Biotech, has recently been provided a “Y” category armed security cover by the Union government, officials said on Tuesday.
Ella, 52, is also the founder of the Hyderabad-based biotechnology company that is manufacturing the Covaxin vaccine approved by India for inoculation against Covid-19.
The company is also engaged in drug discovery, drug development, manufacturing various other vaccines, bio-therapeutics, pharmaceuticals and healthcare products.
(With inputs from agencies)